Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clobetasol propionate for grafted burn wound scarring
ACTRN12612000142831Phase 2Not yet recruiting
- Sponsor
- Burns Unit
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clobetasol in burn injury (2 arms), sponsored by Burns Unit. Primary endpoints: Reduction in thickening and contracture of scar tissue and Reduction in hypertrophic scar formation. Planned start Feb 2012; status: not yet recruiting.
02
Drugs
clobetasol
03
Conditions
burn injury
Beyond the preview
Go deeper on ACTRN12612000142831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000142831.